This site and its domain are for sale. Email the owner if you want to talk about it.

compoundglp.com

What Happened When the GLP-1 Shortages Ended

The shortage ended in February 2025, the grace periods expired, and the vials, as it turns out, mostly stayed where they were.

A row of small glass injection vials and a few syringes on a pharmacy counter beside a blank prescription pad.

On February 21, 2025, the FDA officially declared that there was enough semaglutide. (Technically it declared that the shortage had ended, which is the same announcement in government voice.) For a lot of businesses this was bad news. They had been allowed to sell semaglutide at all only because there wasn’t enough of it.

So, is compounded semaglutide still legal? Narrowly, yes. Broadly, no. A state-licensed 503A pharmacy can still compound it for an individual patient if the prescriber documents a clinically significant difference from the commercial product. A 503B outsourcing facility can only use bulk semaglutide if it appears on the FDA’s bulk substances list or on the shortage list, and as of one source’s writing it was on neither. What compounders lost was the broad permission to mass-produce near-identical copies of the brand-name product, which was most of the business.

Here is the rule underneath all of this. Compounding a copy of an FDA-approved drug is ordinarily prohibited. But sections 503A and 503B of the Food, Drug, and Cosmetic Act carve out an exception for shortages. Under 503B, outsourcing facilities can make large volumes from bulk drug substances, without individual prescriptions, as long as the drug is on the shortage list at the time of compounding, distribution and dispensing. (That last clause will matter.)

Semaglutide and tirzepatide went on the list in 2022, when demand outstripped supply, and compounders came in. The result, in the words of law firm ArentFox Schiff, was a “multibillion-dollar sub-industry.” By October 2024, millions of patients were estimated to be taking compounded GLP-1s, and at the 2024 peak nearly 1 in 3 Americans on a GLP-1 said they got it from a compounding pharmacy. Compounded semaglutide typically cost $150 to $400 a month. None of it was reviewed by the FDA for safety or efficacy, because that is not what the exception does. The exception fills gaps.

Then the gap closed.

The dumb version of ending a shortage

The dumb version goes like this. The FDA looks at supply, decides there is enough, and takes the drug off the list. The exception disappears. Compounders stop. Patients get brand semaglutide, or nothing, or something else.

That is how a light switch works. It is not how a multibillion-dollar sub-industry works, because that has inventory, open prescriptions, patients partway through treatment, and lawyers. (Lots of lawyers.) It also matters who supplied the data behind the switch. For semaglutide, the FDA relied heavily on Novo Nordisk’s production, inventory, supply, wholesaler and projected demand information. For tirzepatide, it reviewed Eli Lilly’s expanded manufacturing capacity alongside input from compounders, patients, telehealth companies and others.

You can sort of see why the compounders did not just say “ah, fair enough.” Industry groups challenged the 503B enforcement deadline and got injunctions that temporarily prevented a complete shutdown of semaglutide compounding. How far those went, and for how long, is not settled by anything I have here.

The grace period version, with beyond-use dates

So the real version is longer. The FDA set phased enforcement deadlines for compounders to wind down. For tirzepatide, the grace period ended February 18, 2025 for 503A pharmacies and March 19, 2025 for 503B outsourcing facilities. For semaglutide, 503B facilities that made product before May 22, 2025 could sell those batches until the expiration date on each vial. In general, product compounded and dispensed before the deadline can be used through its beyond-use date. New compounding after the window closes is not permitted.

This is enforcement discretion, which is a weird idea if you stare at it. The statute says the exception ends when the shortage ends. The agency says it will not come after anyone for a while. It is last call at a bar: the bar is closed, but you can finish the drink in your hand, and the pitcher you ordered two minutes ago. You cannot order another.

The discretion was also partial. Law firm Foley & Lardner noted that the FDA’s policy said it “may still take action regarding violations of other statutory or regulatory requirements” for compounded semaglutide, such as a product being substandard or unsafe, “even within the grace period.” The grace covered the shortage problem. It did not cover every problem.

And here is the number I keep coming back to. The wind-down runs on beyond-use dates: what is already made can be used until that date. A 2025 survey of compounded GLP-1 products found 33 unique products, and only 18% of them provided beyond-use-date information. Eighteen percent of 33 is 5.94. So the official off-ramp for an industry serving millions of people was keyed to a date that about six products in that survey disclosed (presumably exactly six, since products are sort of hard to split). The others presumably had dates somewhere. Just not where the survey looked.

Now the sophisticated version, from the compounder’s side. The dumb version of continuing is to keep making the same copy and hope nobody notices. Something like that happened. Contrary Research reports that after the shortage ended, “some compounders and DTC platforms continued producing compounded GLP-1s, resulting in regulatory scrutiny and legal action from the FDA and Novo Nordisk.”

The sophisticated version uses the door that is still open: the 503A individual patient with a documented clinically significant difference. So the product becomes personalized. A different dose. A different salt (some compounders switched to semaglutide sodium or acetate, which another article here covers). An added ingredient, vitamins, etc.: in that 2025 survey, 48% of products contained combinations, including cyanocobalamin, glycine, niacinamide, docusate or ondansetron. You can almost hear the internal email: “Hey team, quick update, starting Monday our semaglutide is personalized, no action needed on your end.” (I made that email up, obviously.)

Then the vial arrives. It is semaglutide in a vial, at a monthly price that looks like the old one. The long road ends at the same place.

One reading is that this is what 503A is for: medicine is individual, some patients need something the commercial product does not offer, and a prescriber writing that down is doing the job. The other reading is that “clinically significant difference” has become a field on a form, and the difference is whatever fits in the field. The facts do not say which reading fits which pharmacy, and I feel like the answer is often both, in the same building.

The catch is that this stuff is exposed twice: to lawsuits from the companies that hold the drug approvals and to FDA enforcement, a dual legal exposure. As of August 5, 2025, Novo Nordisk had filed 132 complaints in federal courts across 40 states against companies whose marketing and practices around compounded semaglutide, in its view, put patients at risk. I would rather not think about what Novo’s lawyers have planned for complaint 133.

Where the patients went

The dumb version says patients switched back to brand. The facts here do not count where they actually went. Some presumably went to brand, some to personalized products, some to nothing. Not settled.

What is documented is that switching formats has costs of its own. The FDA put out a safety communication in July 2024 on dosing errors with compounded semaglutide, including patients who drew up several times the intended amount because the vial labeling differed from the pen format they had read about. In July 2025 it warned again, citing patients who mistakenly took five to 20 times the intended dose and needed hospitalization. (The dosing errors article on this site has the details.) Look, a pen and a vial are different objects. Moving millions of people between them, back and forth, with each move driven by a list, is going to produce some confusion, lol.

In February 2025 the FDA said there was enough semaglutide. There was. There was also, it turned out, plenty of the other kind, plus a legal reason to keep some of it around.

The shortage ended. The vials did not.

Sources

  1. How GLP-1s Broke Healthcare Distribution | Contrary Research
  2. GLP-1 Drugs: FDA Removes Semaglutide from the Drug Shortage List | Foley & Lardner
  3. The Semaglutide Shortage Is Ending: What’s Next For Compounded Drugs?
  4. Compounded GLP-1 Marketing After the Shortage Ended
  5. Major Update on GLP-1 Litigation involving Compounding ...
  6. Semaglutide Compounding Pharmacy: What's Legal In 2026
  7. The Shot Heard ‘Round the Pharmacy’: FDA Takes Aim at GLP-1 Compounders | ArentFox Schiff
  8. Businesses continue to sell compounded semaglutide, tirzepatide
  9. Semaglutide Salt Forms: Why the Base Matters
  10. Compounded GLP-1s: Why doctors worry and the FDA is cracking down
  11. Semaglutide Cost San Antonio: Compounded vs Brand – Dr. Rogers Centers
  12. Compounded Tirzepatide: Meaning, Risks, Regulator Warnings
  13. Compounding After a Drug Leaves the Shortage List
  14. America's Poison Centers - GLP-1
  15. Compounded Semaglutide Dosage Chart: Titration Guide
  16. Fifth Circuit Upholds FDA on GLP-1 Shortage Decisions
  17. Compounded Semaglutide and Tirzepatide Products Use Unique Formulations but Efficacy and Safety Largely Unknown
  18. FDA clarifies position on compounding semaglutide sodium
  19. The Semaglutide Shortage Is Ending: What’s Next For Compounded Drugs?
  20. FDA MedWatch - FDA Alerts Health Care Providers, Compounders and Patients of Dosing Errors Associated with Compounded Injectable Semaglutide Products
  21. Novo Nordisk expands legal action to protect US patients from unsafe, non-FDA-approved compounded "semaglutide"
  22. Compounded Semaglutide: Meaning and Why Regulators Warn

Compound GLP explains the law and published research. It is not medical or legal advice, and it never recommends a dose, a pharmacy or a product. Talk to a clinician before you start, stop or change any medicine.

Read next